Avenue Therapeutics, Inc.
ATXI
$0.26
-$0.02-8.20%
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -49.73% | -65.60% | -32.30% | -34.02% | -37.41% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -36.13% | -62.52% | -40.16% | -77.06% | -60.80% |
| Operating Income | -338.05% | 62.52% | 40.16% | 77.06% | 110.52% |
| Income Before Tax | -309.73% | 62.59% | 53.43% | 77.58% | 112.18% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -309.73% | 62.59% | 53.43% | 77.58% | 112.18% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | 13.33% | -18.18% | -33.33% |
| Net Income | -305.97% | 62.47% | 54.08% | 77.80% | 112.44% |
| EBIT | -338.05% | 62.52% | 40.16% | 77.06% | 110.52% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -299.05% | 66.15% | 72.66% | 88.84% | -92.76% |
| Normalized Basic EPS | -296.84% | 66.08% | 65.03% | 88.91% | 104.43% |
| EPS Diluted | -299.05% | 66.15% | 72.66% | 88.84% | -92.76% |
| Normalized Diluted EPS | -296.84% | 66.08% | 65.03% | 88.91% | 104.43% |
| Average Basic Shares Outstanding | 3.50% | 10.87% | 68.00% | 98.95% | 184.81% |
| Average Diluted Shares Outstanding | 3.50% | 10.87% | 68.00% | 98.95% | 184.81% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |